L3VLUP
ProSign in

SNY · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

SNYLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • SNY
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterSNYLLY
Q3 202011 holders, $3.4bn33 holders, $14.1bn
Q4 20207 holders, $3.3bn29 holders, $17.3bn
Q1 20217 holders, $4.5bn24 holders, $23.0bn
Q2 20215 holders, $4.9bn24 holders, $27.8bn
Q3 20217 holders, $6.0bn31 holders, $29.9bn
Q4 20217 holders, $6.2bn31 holders, $34.7bn
Q1 20227 holders, $6.5bn24 holders, $35.3bn
Q2 20227 holders, $6.1bn33 holders, $42.7bn
Q3 20229 holders, $4.6bn31 holders, $43.4bn
Q4 202210 holders, $5.9bn31 holders, $46.6bn
Q1 202312 holders, $6.6bn33 holders, $44.3bn
Q2 20239 holders, $6.1bn37 holders, $59.6bn
Q3 20239 holders, $5.9bn44 holders, $67.6bn
Q4 20237 holders, $5.3bn45 holders, $73.6bn
Q1 20247 holders, $5.1bn41 holders, $95.3bn
Q2 202411 holders, $5.5bn43 holders, $110bn
Q3 202411 holders, $6.5bn45 holders, $107bn
Q4 20248 holders, $5.1bn46 holders, $93.9bn
Q1 20258 holders, $6.2bn42 holders, $98.4bn
Q2 20257 holders, $4.8bn43 holders, $93.2bn
Q3 20256 holders, $3.8bn39 holders, $86.7bn
Q4 20256 holders, $3.0bn41 holders, $123bn
Q1 20266 holders, $1.7bn39 holders, $106bn
Q2 20267 holders, $1.6bn44 holders, $132bn
SNY

Sanofi

Holders
7
Reported value
$5.1bn
Buyers
4
Sellers
2

Breadth +2 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
41
Reported value
$95.3bn
Buyers
15
Sellers
27

Breadth -12 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 44 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only SNY (3)

First Eagle Investment Management LLC, Hudson Bay Capital Management LP, Soros Fund Management LLC

Only LLY (37)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., GAMCO Investors Inc, Holocene Advisors LP, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Moore Capital Management LP, Neuberger Berman Group LLC, Point72 Asset Management LP, Polen Capital Management LLC, Renaissance Technologies LLC, and 12 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →